68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. (July 2016)
- Record Type:
- Journal Article
- Title:
- 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. (July 2016)
- Main Title:
- 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT
- Authors:
- Bluemel, Christina
Krebs, Markus
Polat, Bülent
Linke, Fränze
Eiber, Matthias
Samnick, Samuel
Lapa, Constantin
Lassmann, Michael
Riedmiller, Hubertus
Czernin, Johannes
Rubello, Domenico
Bley, Thorsten
Kropf, Saskia
Wester, Hans-Juergen
Buck, Andreas K.
Herrmann, Ken - Abstract:
- Abstract : Purpose: Investigating the value of 68 Ga-PSMA-PET/CT in biochemically recurring prostate cancer patients with negative 18 F-choline-PET/CT. Patients and Methods: One hundred thirty-nine consecutive patients with biochemical recurrence after curative (surgery and/or radiotherapy) therapy were offered participation in this sequential clinical imaging approach. Patients first underwent an 18 F-choline-PET/CT. If negative, an additional 68 Ga-PSMA-PET/CT was offered. One hundred twenty-five of 139 eligible patients were included in the study; 32 patients underwent additional 68 Ga-PSMA-PET/CT. Patients with equivocal findings (n = 5) on 18 F-choline-PET/CT and those who declined the additional 68 Ga-PSMA-PET/CT (n = 9) were excluded. Images were analyzed visually for the presence of suspicious lesions. Findings on PET/CT were correlated with PSA level, PSA doubling time (dt), and PSA velocity (vel). Results: The overall detection rates were 85.6% (107/125) for the sequential imaging approach and 74.4% (93/125) for 18 F-choline-PET/CT alone. 68 Ga-PSMA-PET/CT detected sites of recurrence in 43.8% (14/32) of the choline-negative patients. Detection rates of the sequential imaging approach and 18 F-choline-PET/CT alone increased with higher serum PSA levels and PSA vel. Subgroup analysis of 68 Ga-PSMA-PET/CT in 18 F-choline negative patients revealed detection rates of 28.6%, 45.5%, and 71.4% for PSA levels of 0.2 or greater to less than 1 ng/mL, 1 to 2 ng/mL, andAbstract : Purpose: Investigating the value of 68 Ga-PSMA-PET/CT in biochemically recurring prostate cancer patients with negative 18 F-choline-PET/CT. Patients and Methods: One hundred thirty-nine consecutive patients with biochemical recurrence after curative (surgery and/or radiotherapy) therapy were offered participation in this sequential clinical imaging approach. Patients first underwent an 18 F-choline-PET/CT. If negative, an additional 68 Ga-PSMA-PET/CT was offered. One hundred twenty-five of 139 eligible patients were included in the study; 32 patients underwent additional 68 Ga-PSMA-PET/CT. Patients with equivocal findings (n = 5) on 18 F-choline-PET/CT and those who declined the additional 68 Ga-PSMA-PET/CT (n = 9) were excluded. Images were analyzed visually for the presence of suspicious lesions. Findings on PET/CT were correlated with PSA level, PSA doubling time (dt), and PSA velocity (vel). Results: The overall detection rates were 85.6% (107/125) for the sequential imaging approach and 74.4% (93/125) for 18 F-choline-PET/CT alone. 68 Ga-PSMA-PET/CT detected sites of recurrence in 43.8% (14/32) of the choline-negative patients. Detection rates of the sequential imaging approach and 18 F-choline-PET/CT alone increased with higher serum PSA levels and PSA vel. Subgroup analysis of 68 Ga-PSMA-PET/CT in 18 F-choline negative patients revealed detection rates of 28.6%, 45.5%, and 71.4% for PSA levels of 0.2 or greater to less than 1 ng/mL, 1 to 2 ng/mL, and greater than 2 ng/mL, respectively. Conclusions: The sequential imaging approach designed to limit 68 Ga-PSMA imaging to patients with negative choline scans resulted in high detection rates. 68 Ga-PSMA-PET/CT identified sites of recurrent disease in 43.8% of the patients with negative 18 F-choline PET/CT scans. … (more)
- Is Part Of:
- Clinical nuclear medicine. Volume 41:Number 7(2016)
- Journal:
- Clinical nuclear medicine
- Issue:
- Volume 41:Number 7(2016)
- Issue Display:
- Volume 41, Issue 7 (2016)
- Year:
- 2016
- Volume:
- 41
- Issue:
- 7
- Issue Sort Value:
- 2016-0041-0007-0000
- Page Start:
- Page End:
- Publication Date:
- 2016-07
- Subjects:
- choline-PET/CT -- PSMA-PET/CT -- prostate cancer -- recurrence -- restaging
Nuclear medicine -- Periodicals
Radioisotope scanning -- Periodicals
Nuclear Medicine -- Periodicals
616.07575 - Journal URLs:
- http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&NEWS=n&PAGE=toc&D=ovft&AN=00003072-000000000-00000 ↗
http://journals.lww.com/nuclearmed/pages/default.aspx ↗
http://journals.lww.com ↗ - DOI:
- 10.1097/RLU.0000000000001197 ↗
- Languages:
- English
- ISSNs:
- 0363-9762
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.314000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 1066.xml